From the December lows of around $6, Daxor shares shot up more than 300% to a recent high of $20 in early March. The rally was, in my opinion, justified by the fundamental strength of their product, the BVA-100....
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at the Annual Meeting of the American College...
Tailwinds Research - First off, let’s get into the data. You recently announced positive results at an industry conference. Can you speak about the significance of these? Michael Feldschuh - The recent results at SCCM confirm that our test has...
Tailwinds' Take: we eventually expect to see a sharp uptick in growth from this already strong rate as the implications of the pivotal trial generate increased interest from the medical community. That likely starts to show itself this summer. NEW...
Daxor Corporation  February 28, 2019 Dear Fellow Shareholder: Daxor Corporation (“Daxor”or the “Company”) is an investment company with medical instrumentation and biotechnology operations. We have attached a report of our portfolio holdings and investment activity for the year ended December 31, 2018....
Tailwinds' Take: "Less blood draws, quicker results". This research further positions the BVA-100 as a must have for hospitals. The big catalyst here? We expect to start seeing these clinical results translate into sales in the near future. When...
Tailwinds' Take: Looking forward to seeing more data on the BVA-100. The medical community is just waking up to the incredible savings in mortality associated with proper blood volume management. NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE...

Daxor Emerges

Accurate blood volume monitoring can save lives and reduce medical costs The BVA 100 is the only approved product on the market Hospitals are incentivized to adopt the product The market opportunity is large Daxor emerges Similar to how...
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of Sales. "Guido joins Daxor with...
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a BVA-100...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.